(NewsNation) — Drugmakers Eli Lilly and Novo Nordisk are reportedly working out a deal with the Trump administration to cut the prices of their weight loss drugs.
According to Reuters, Lilly could offer the lowest dose of its popular weight loss drug Zepbound at $149 a month, and Novo’s Wegovy could be offered at $299 a month through TrumpRx. In return, the two drugs could also gain coverage under Medicare.
Eli Lilly is also negotiating for a government voucher that would expedite federal review of a weight loss pill it’s looking to bring to the market, according to the Wall Street Journal.
President Donald Trump has increased pressure on drug companies to lower their medication costs in recent months.
In May, he signed an executive order to implement a “most-favored nation” policy, which would cap costs based on other countries’ prescription prices, a move Trump said could drop prices for Americans by 30% to 80%.
Since that executive order was signed, Trump has reached deals with drugmakers Pfizer and AstraZeneca to lower drug costs.
Spokespersons for both Eli Lilly and Novo Nordisk told the Wall Street Journal they are in negotiations with the administration and are looking to “promote affordability” of their medications.
Go To Source | Author: Jordan Perkins
« Sauce Gardner is the biggest winner from the NFL’s trade deadline
Tom Bergeron returning to ‘Dancing with the Stars’ after forced exit »